Testing different immune-suppressing treatments for membranous kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have idiopathic membranous nephropathy (your doctors say it’s not caused by another condition).
- You are post-menopausal, or you can use effective birth control and are not planning pregnancy.
- You’ve been off steroids and mycophenolate for over 1 month, and off alkylating drugs or rituximab for over 6 months.
- You’ve used an ACE inhibitor or ARB for at least 3 months with blood pressure that was controlled (unless you can’t tolerate it).
- Your urine protein is at least 4 grams per day, and it has not dropped more than 50% from your usual baseline.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
Hear when a new Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.